patients with breast cancer (n=65), cervical cancer (n=32), haematological malignancies (n= 32), rare cancer types (n=30) and melanoma (n=21). Questions were asked regarding possibilities of ionized imaging, chemotherapy, hormonal therapy or immunotherapy during pregnancy and possible effects on the child, the sequence of the different treatment components and questions on fertility. Response rate of the questionnaire was 54%. Overall satisfaction with the recommendations of the MDT was high, and 94% of the respondents informed their patients about consulting the MDT and felt supported by the received recommendations.

Conclusion* A national MDT for cancer and pregnancy is frequently consulted and highly appreciated by physicians. Next to that, it increases expertise of its members about this rare coincidence of cancer and pregnancy. We highly recommend to establish an (inter)national MDT in each country. Figure 1 shows the important steps necessary to establish an MDT for cancer in pregnancy based on our experience.

324 COMPARISON OF SERUM HE4 AND CA125 LEVELS IN THE EARLY POSTPARTUM PERIOD

¹R Delic*, ²M Stefanovic, ³S Krivec, ¹J Koren. ¹General and Teaching Hospital Celje, Department of Gynecology and Obstetrics, Celje, Slovenia; ²Sestre milosrdnice University Hospital Center, Department of Clinical Chemistry, Zagreb, Croatia; ³General and Teaching Hospital Celje, Department of Laboratory Medicine, Celje, Slovenia

10.1136/ijgc-2021-ESGO.239

Introduction/Background* This study was undertaken to evaluate and compare CA125 and HE4 serum concentrations in the early postpartum period.

Methodology In a prospective designed, monocentric study (Department of Gynecology & Obstetrics, General and Teaching Hospital, Celje, Slovenia, EU), 68 women who were in the 1-3rd day of postpartum period were included in the study.

HE4 and CA125 levels were obtained and analysed with regard to each day of postpartum period (1st, 2nd and 3rd day after delivery) as well as regarding the method of delivery (vaginal delivery; n=46, elective (EICS); n=15 and emergency caesarean section (EmCS); n=8).

CA125 and HE4 levels were measured in consideration of their reference intervals less than 35 IU/ml and less than 140 pmol/l, respectively (Elecys CA 125 II[®] assay and Elecys HE4[®] assay, Roche Diagnostics Ltd., Rotkreuz, Switzerland).

Data were analysed by ANOVA (MedCalc Software, Maria-kerke, Belgium).

Result(s)* The CA-125 levels were frequently above the conventional cut-off limit of 35 IU/mL; differences in mean concentrations between study groups were not found to be statistically significant (Group I, n=44, 1st day after delivery, mean = 39,4 IU/ml; Group II, n = 19, 2nd day after delivery, mean = 32,8 IU/ml; Group III, n =5, 3rd day after delivery, mean = 38,8 IU/ml, p = 0,708).

Regarding the method of delivery, women in the vaginal delivery group had seemingly higher levels of CA125 than the women in both caesarean section groups, but still not statistically significant (44,0 IU/ml vs 29,7 IU/ml (EICS) and 21,5 IU/ml (EmCS), respectively; p=0,057).

HE4 levels were within reference range and significant difference was also not observed between 1st, 2nd and 3rd day postpartum (Group I, n=44, 1st day after delivery, mean = 60,3 pmol/l; Group II, n = 19, 2nd day after delivery, mean

Abstract 324 Figure 1

Abstract 324 Figure 2

= 54,3 pmol/l; Group III, n =5, 3rd day after delivery, mean = 49,2 pmol/l, p = 0,096).

Regarding the method of delivery, women in the vaginal delivery group had significantly lower levels of HE4 than the women in both caesarean section groups (54,5 pmol/l vs 65,7 pmol/l (EICS) and 61,1 pmol/l (EmCS), respectively; p=0,015).

Conclusion* According to our preliminary results, HE4 is more reliable marker of malignancy during the early postpartum period than CA125.

348 CONSERVATIVE SURGERY AND OVERALL SURVIVAL IN YOUNG WOMEN WITH A DIAGNOSIS OF BORDERLINE OVARIAN TUMOR

M Laseca Modrego*, O Arencibia Sanchez, D González García-Cano, AF Rave Ramirez, A Martín Martínez. Maternal Child Hospital of the Canary Islands, Oncology Gynecology Department, Las Palmas de Gran Canaria, Spain

10.1136/ijgc-2021-ESGO.240

Introduction/Background* Radical surgery is the main treatment for Borderline Ovarian Tumors. Surgery includes hysterectomy, double adnexectomy, omentectomy and appendectomy if the histological line is mucinous.

Due to the excellent prognosis, some authors affirm that it is possible to perform a conservative surgery in young women who have not fulfilled their reproductive desire, without having repercussions in terms of overall survival.

The objective of the study was to know the treatment and the overall survival of the Borderline Ovarian Tumors in young women.

Methodology A retrospective cohort study was conducted. The study period was from January 2012 to January 2020. A total of 131 women with Borderline Ovarian Tumors were included in the study. Information was collected about: demographic data, diagnosis, type of surgery performed, disease-free survival, and overall survival. Two cohorts were established: conservative treatment (n = 37) vs radical treatment (n = 94).

Result(s)* 131 women with a diagnosis of Borderline Ovarian Tumors were diagnosed, representing 16.7% of all the malignant ovarian tumors within this period (n = 784). 91.5% were diagnosed in Stage I according to the FIGO classification and the most histological line frequent was the mucinous (49.2%). The risk of global relapse was 6.2% and overall survival was 95.4%.

Regarding the group of patients who underwent conservative surgery, the risk of relapse was 13.5% (n = 5) compared to 3.2% (n = 3) in the group radical treatment, (p = 0.042).

The Overall survival was 100% in women with conservative surgery compared to radical surgery, 94.6%, (p = 0.130).

Conclusion* Borderline Ovarian Tumors present excellent prognosis, obtaining great positive results in overall survival regarding the performance of conservative surgery in young women with unfulfilled reproductive desire.

407

SUCCESSFUL LIVE BIRTH TWINS AFTER CHEMOTHERAPY DUE CARCINOMA OF COLON DURING PREGNANCY'S: A CASE REPORT

¹B Jocić Pivac*, ¹V Krsić, ²J Milojević. ¹GAK Narodni front, obgyn, Belgrade, Serbia; ²general hospital Lazarevac, obgyn, Belgrade, Serbia

10.1136/ijgc-2021-ESGO.241

Introduction/Background* Diagnosing cancer during pregnancy is uncommon. Approximately one in every 1000 pregnancies is diagnosed with cancer during the antenatal period. Cervical cancer and breast cancer are among the most commonly identified cancers during pregnancy but gastrointestinal, urological, and lung cancers have a lower rate of incidence.

In this case we discuss successful management of a patient who was diagnosed with carcinoma of ascendant colon during the antenatal period.

Methodology 42 years old women (PARA -0, GRAV -) was admitted in our hospital in 12 weeks gestations because of pain in abdomen. In previous history, before 4 years she had breast cancer surgery when a local tumorectomy was performed with chemotherapy in six cycles. The pregnancy occurred after IVF. She had all symptoms of hyperstimulation syndromes with big ovaries in diameter of 12 cm and ascites. She did not complain any gastrointestinal problem. After two weeks of therapy for hyperstimulation syndromes she had increasing abdominal pain. We performed laparotomy.

Result(s)* After opening the abdomen, we found a tumor of the ascending colon and performed a right hemicolectomy

with bilateral ovariectomy. The omentum was full of metastases. We performed a colostomy. Her abdominal pain was lost after surgery. She received five cycle of chemotherapy of FOLOFOX. She was delivered by Caesarean section at the 33rd weeks of pregnancy. She was discharged on the seven postoperative day because of her good general condition, as well as that of her newborns, two girls.

Conclusion* Carcinoma and pregnancy bring us two main problems. One is to discover right diagnosis and the other is to choose optimal treatment because it requires considerations of both pregnant women and unborn fetus. Colorectal carcinomas are rare and definitive treatment depends on the term of pregnancy. Generally, definitive surgical therapy is offered if the diagnosis is made early in the pregnancy and deferred until after parturition if it made in the late pregnancy. In our case we performed even chemotherapy because of due to the advanced stage of the disease

537

FERTILITY SPARING TREATMENT IN PATIENTS WITH ENDOMETRIAL CANCER (FERT-ENC) FROM THE SPANISH INVESTIGATIONAL NETWORK GYNECOLOGIC ONCOLOGY GROUP

¹V Lago*, ¹MT Marina Martín, ²M Laseca Modrego, ³B Gil Ibanez, ⁴JR Rodriguez, ⁵J Domingo, ⁶L Minig, ¹P Padilla Iserte, ²O Arencibia Sanchez, ⁷M Sala Ferichola, ⁸M Munmany, ⁹B Martín, ^{10,11}S Iacoponi, ¹²S Cabrera, ¹³P Coronado, ¹⁴J Utrilla Layna, ¹⁵A Bataller Calatayud, ¹⁶G Fiol, ¹⁷S Corbalán, ¹⁸S Domingo. ¹University Hospital La Fe, Spain; ²Maternal and Child University Hospital of the Canarias; ³University Hospital 12 de Octubre; ⁴Clinic and University Hospital Virgen de la Arrixaca; ⁵IVI Las Palmas; ⁶CEU Cardenal Herrera University; ⁷General University hospital of Alicante; ⁸Clinic University Hospital; ⁹University Hospital Getafe; ¹⁰Hospital Quironsalud Madrid; ¹¹University Hospital Quironsalud Madrid, Gynecology, Pozuelo de Alarcón, Spain; ¹²University hospital Vall d'hebron; ¹³Clinic University Hospital San Carlos; ¹⁴University Hospital Fundación Jiménez Díaz; ¹⁵University Hospital of La Rivera; ¹⁶University Hospital Torrecárdenas; ¹⁷University Hospital Los Arcos

10.1136/ijgc-2021-ESGO.242

Introduction/Background* The primary objective was to evaluate the response rate of conservative treatment in endometrial cancer and the secondary objective was to assess oncological, fertility and obstetric outcomes in fertility preservation patients

Methodology This was a multi-centre, observational, retrospective study of endometrial cancer patients who underwent fertility-sparing treatment in Spanish centres (January 2010–2020). Seventy-three patients with stage IA, endometrioid adenocarcinoma of the uterus were included in the study.

Result(s)* The levonorgestrel intrauterine device (LNG-IUD) was the most used method (53.4%), followed by megestrol acetate (20.5%) and medroxyprogesterone acetate (16.4%). During the 24-month follow-up, the rate of complete response to the fertility-sparing management was 74% (n = 54/73) and 8.2% (n = 6/73) patients presented a partial response. Additionally, 13 (17.8%) patients presented with persistent disease and six (8.2%) patients relapsed after response. The use of LNG-IUD was associated with a higher complete response rate (LNG-IUD 87.2% vs. others 58.8%; p = 0.01). Surgical treatment (at least hysterectomy) was completed in 44 (60.3%) patients. Four (5.5%) patients presented with relapse after surgery being associated with it the final stage FIGO III (p = 0.036), myometrial invasion >